In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo
用户k7g3AjDeE8DM
2个月前
63
10
已完结
1. 系统已在2025-08-04 09:09:01对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.7326/ANNALS-25-01791-JC
文献链接: https://www.acpjournals.org/doi/10.7326/ANNALS-25-01791-JC
其他信息:
出版社: American College of Physicians
作者: Aarti Thakkar; L. Kristin Newby; undefined undefined
全文下载地址: https://www.acpjournals.org/doi/pdf/10.7326/ANNALS-25-01791-JC
